Skip to Content
Stock Analyst Update

Morningstar Analyst Research: The Week in Stocks

As New Year revelries approach, we highlight a diverse bag of stocks.

It's been a slow week in the markets, with lots of people taking a vacation between Christmas and New Year's Day. And with much of the nation gripped by ice, snow, and bitter cold, it's been a good time to snuggle next to a crackling fire rather than go out and brave the elements. But we at Morningstar are like the post office--neither snow, nor rain, nor gloom of night can stay us from analyzing our appointed stocks. We've been as busy as ever updating our stock analyses and adding new ones, and this week we reached a milestone when we completed our 1,000th stock analysis.

As a way of highlighting the diversity of our stock coverage, here are some of the new or recently updated stock analyses you can find, ranging from blue chips to startups. Premium Morningstar.com members get access to all 1,000 stock analyses and 2,000 fund analyses, along with lots of other great tools and extras. If you're not already a member, click on the link at the end of this article for a free 30-day trial.

  • American Express (AXP) has been one of the best-performing and most consistent financial stocks of the past few years. But CEO Harvey Golub, the architect of that remarkable run, is stepping down as of the end of 2000. Will Amex still be a stock you can't leave home without? Find out here
  • Kmart (KM), once the top dog among discount retailers, has been pushed off center stage by faster-growing competitors such as Wal-Mart Stores (WMT) and Target (TGT). It's been opening bigger stores and trying to revitalize its image, but is that enough?
  • The World Wrestling Federation (WWF) has become a cultural phenomenon, for better or for worse. Now it's taking on the National Football League with the upcoming XFL. Is this violent multimedia empire worth investing in, or will the XFL venture body slam its shares?
  • The biotechnology industry took investors on a roller-coaster ride in 2000. One of the more interesting companies in this volatile but promising sector is Affimetrix (AFFX), a leader in microarrays, or gene chips. Will this technology live up to the hype and make investors rich? We'll give you our view.
  • Technology stocks has been hard-hit lately, and Vishay Intertechnology (VSH), which makes components for a variety of electronic gizmos, has been one of the victims. Is this stock really a dog, or has it been unfairly beaten down? Click here to find out.

Get Morningstar's unbiased analyses of 1000 stocks and 2000 funds, free for 30 days.